Wall Street Remains Nervous About GLP-1
Wall Street’s concerns about the impact of GLP-1 on medical device makers were heightened after glucose-monitoring device vendor Dexcom (DXCM) cut its full-year forecast after reporting weaker-than-expected results last week. However, Dexcom’s troubles appear unrelated to the weight-loss and diabetes drug frenzy, as rivals like Abbott (ABT) and Medtronic (MDT) have not been pressured by…